We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Articles

Results 1 to 5 of 6
Most popular |Most recent


Securities Class Actions in the Life Sciences Sector

USA - May 1 2019 This year-in-review addresses developments in securities class actions brought against life sciences companies in 2018...

Norman J.Blears, Robin E. Wechkin, Sarah A. Hemmendinger.

SEC Explains Regulation G Exemption for M&A Forecasts

USA - October 18 2017 Yesterday, the Staff of the U.S. Securities and Exchange Commission (SEC) elaborated on existing rules and interpretations to make clear that, in the...

Thomas J. Kim, Jennifer Fitchen, James W. Ducayet, Norman J.Blears, Martin A. Wellington.

Securities Class Actions in the Life Sciences Sector

USA - May 5 2017 This year-in-review addresses developments in securities class actions brought against life sciences companies in 2016. We begin with an overview and...

James W. Ducayet, Hille R. Sheppard, David F. Graham, Norman J.Blears, Yvette Ostolaza, Jack W. Pirozzolo, Robert Pietrzak, Andrew W. Stern, Walter C.Carlson.

Securities class actions in the life sciences sector

USA - June 10 2016 Before analyzing these decisions, we briefly take note of United States Supreme Court activity in the area of securities litigation generally in 2015...

Hille R. Sheppard, David F. Graham, Norman J.Blears, Robert Pietrzak, Walter C.Carlson.

Basic upheld in Halliburton: defendants may rebut price impact

USA - June 23 2014 The U.S. Supreme Court this morning, in Halliburton Co. v. Erica P. John Fund, Inc., No. 13-317 (U.S. June 23, 2014), preserved (by a 6-3 vote in an...

Daniel A. McLaughlin, David F. Graham, Robert Pietrzak.